Publication
First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (7)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 7
- cancerMelanomacivic_curation1.00
- cancerOvarian Carcinomacivic_curation1.00
- drugPictilisibcivic_curation1.00
- geneBRAFcivic_curation1.00
- genePIK3CAcivic_curation1.00
- variantBRAF V600Ecivic_curation1.00
- variantPIK3CA Amplificationcivic_curation1.00
Curated evidence
Evidence citing this paper (2)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 25370471
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| BRAF V600E1 | ||||||||
| Pictilisib | Melanoma | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID757One patient with BRAF V600E mutated melanoma (with no detected PI3K pathway deregulation) had a partial response on treatment with pictilisib, a PI3K inhibitor, for 9.5 months. Study was a phase-1 wit… (full text at CIViC) PMID 25370471 · Sarker et al., 2015 · Open in CIViC | civic |
| PIK3CA Amplification1 | ||||||||
| Pictilisib | Ovarian CarcinomaALIAS | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID756One platinum-refractory epithelial ovarian cancer patient with PTEN loss and PIK3CA amplification had a partial response on treatment with PI3K inhibitor pictilisib (GDC-0941) in this phase 1 study. A… (full text at CIViC) PMID 25370471 · Sarker et al., 2015 · Open in CIViC | civic |